Glucagon-like Peptide 1 (GLP-1) Analogues Market to Reach US$ 299.08 Billion by 2033 at 17.6% CAGR, Driven by Rising Diabetes & Obesity Prevalence and Expanded Indications

According to DataM Intelligence, the global Glucagon-like Peptide 1 (GLP-1) Analogues market reached US$ 62.81 billion in 2024 and is expected to reach US$ 299.08 billion by 2033, growing at a CAGR of 17.6% during the forecast period 2025-2033, driven by surging global diabetes and obesity rates, strong adoption of long-acting GLP-1 agonists (Ozempic, Trulicity, Mounjaro, Wegovy, Zepbound) for glycemic control and weight loss, expanding oral formulations (Rybelsus), increasing use in subcutaneous and oral routes.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?jd

United States Key Industry Developments

☑️ January 2026: Eli Lilly and Company expanded U.S. access to Mounjaro and Zepbound with new insurance coverage and patient assistance programs, driving significant uptake for obesity and type 2 diabetes management.
☑️ January 2026: Novo Nordisk A/S reported record prescriptions for Ozempic, Wegovy, and Rybelsus, launching enhanced digital support tools for patient adherence and weight tracking.
☑️ December 2025: Sanofi advanced its GLP-1 portfolio with updated real-world evidence for Soliqua and Lyxumia, targeting improved cardiovascular outcomes in type 2 diabetes patients.

Japan Key Industry Developments

☑️ January 2026: Japanese pharmaceutical companies accelerated regulatory approvals and launches of GLP-1 analogues for type 2 diabetes, supported by updated national diabetes management guidelines emphasizing weight management.
☑️ January 2026: Local and global players showcased advanced long-acting GLP-1 formulations at major Tokyo diabetes congresses, focusing on oral and subcutaneous options for aging populations.
☑️ December 2025: Growing integration of GLP-1 therapies in Japan's diabetes clinics and hospitals, driven by increasing obesity-related comorbidities and demand for convenient administration routes.

Key Mergers and Acquisitions

✦ January 2026: Eli Lilly and Company acquired a biotech firm developing next-generation dual GLP-1/GIP agonists to expand its obesity and diabetes portfolio beyond Mounjaro and Zepbound.
✦ December 2025: Novo Nordisk A/S completed a strategic acquisition of a peptide synthesis innovator to enhance manufacturing scale for semaglutide-based products (Ozempic, Wegovy, Rybelsus).
✦ November 2025: Boehringer Ingelheim licensed a novel GLP-1 analogue candidate from a research partner to advance its pipeline for type 2 diabetes and obesity indications.

Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=glucagon-like-peptide-1-analogues-market

Market Segmentation Analysis

By Product: Ozempic and Wegovy (semaglutide) hold significant share due to strong efficacy in diabetes control and weight loss; Mounjaro and Zepbound (tirzepatide) grow fastest with dual GLP-1/GIP action; Trulicity, Rybelsus, Saxenda, Victoza, and Others expand for various dosing and indication preferences.

By Type: Long-acting GLP-1 Agonists dominate with weekly dosing convenience and sustained glycemic control; Short-acting GLP-1 Agonists remain relevant for specific postprandial glucose management.

By Route of Administration: Subcutaneous dominates with established injectable pens for weekly and daily use; Oral grows rapidly with Rybelsus and emerging oral formulations offering patient convenience.

By Application: Type 2 Diabetes Mellitus accounts for the largest share with primary indication for glycemic control; Obesity grows fastest with expanded approvals for weight management (Wegovy, Zepbound); Others include cardiovascular risk reduction and NASH exploration.

By Distribution Channel: Retail Pharmacies lead with widespread availability and patient counseling; Hospital Pharmacies follow for specialty and injectable products; Online Pharmacies expand rapidly with home delivery and subscription models.

Regional Insights

North America commands the largest market share in the global Glucagon-like Peptide 1 (GLP-1) Analogues market, supported by high obesity and diabetes prevalence, rapid FDA approvals for weight-loss indications (Wegovy, Zepbound), strong reimbursement for GLP-1 therapies, advanced healthcare infrastructure, and significant R&D investment by leading pharmaceutical companies.
Asia-Pacific is the fastest-growing region, fueled by rising diabetes and obesity rates in China, India, and Southeast Asia, increasing healthcare access and diagnosis, growing acceptance of GLP-1 agonists for glycemic control and weight management, expanding retail and online pharmacy channels, and aggressive market entry by global players.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glucagon-like-peptide-1-analogues-market?jd

Key Players

The market includes major global players such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi, AstraZeneca, Boehringer Ingelheim, Inc., Glenmark Pharmaceuticals Ltd., Hanmi Pharm. Co., Ltd., Amgen Inc., Gmax Biopharm., Sciwind Biosciences Co., Ltd., and others.

Key Highlights (Top 5 Key Players)

✦ Eli Lilly and Company - Leading with Mounjaro and Zepbound (tirzepatide), dominating dual GLP-1/GIP agonist segment for superior weight loss and diabetes control.
✦ Novo Nordisk A/S - Dominant in GLP-1 market with Ozempic, Wegovy, Rybelsus, and Victoza, pioneering semaglutide for diabetes and obesity management worldwide.
✦ Sanofi - Strong presence with established GLP-1 therapies like Soliqua and Lyxumia, focusing on combination approaches for type 2 diabetes.
✦ AstraZeneca - Key player with Bydureon and other GLP-1 analogues, emphasizing cardiovascular outcome benefits and long-acting formulations.
✦ Boehringer Ingelheim - Advancing GLP-1-based therapies in collaboration with partners, targeting diabetes, obesity, and related comorbidities.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.